Bronchogen is a short peptide bioregulator developed within Vladimir Khavinson's tissue-specific peptide program. It is studied in relation to the bronchi and other airway tissues. Research discussed here concerns airway aging, mucus clearance, chronic obstructive airway disease and recovery after infection, with attention to bronchial epithelial cell function.
What Is Bronchogen?
Bronchogen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson's team targeting bronchopulmonary tissue — specifically the bronchi and bronchioles. It is one of the organ-specific cytomedins in the Khavinson system, designed to restore normal functional gene expression in aging or damaged bronchial epithelial cells. It was developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Target Tissue and Aging
The bronchial epithelium serves as the primary interface between the respiratory system and the external environment. With aging, bronchial epithelial cell function declines: mucociliary clearance slows, surfactant production decreases, and local immune defense weakens. Bronchogen is designed to restore normal bronchial cell activity by acting on chromatin structure and normalizing the epigenetic regulation of key functional genes.
Research Applications
Animal studies have shown Bronchogen to reduce morphological signs of bronchial aging, improve mucociliary clearance parameters, and enhance local bronchial immune defense. Russian clinical research has documented improvements in respiratory function parameters and reduction in recurrent respiratory infections in elderly subjects receiving Bronchogen as part of comprehensive bioregulator protocols.
Quick Reference
Member reference tables summarize the compound's research parameters.
Bronchogen was specifically developed to restore normal functional gene expression in aging bronchial epithelial cells. Aging bronchial epithelium shows reduced mucociliary transport velocity, impaired surfactant production, and weakened barrier function. Animal studies demonstrate that Bronchogen administration normalizes these parameters and reduces morphological signs of bronchial aging.
Chronic Obstructive Airway Disease
Russian Clinical Data
Russian clinical research documents improvements in respiratory function parameters and reduction in recurrent respiratory infections in elderly subjects receiving Bronchogen as part of comprehensive bioregulator protocols. The mechanism — epigenetic normalization of bronchial cell gene expression — is consistent with the broader Khavinson bioregulator model.
Post-Infection Pulmonary Recovery
Emerging Research
Khavinson groups have explored bronchial peptides in post-infection recovery contexts, including bacterial pneumonia and viral respiratory illness. The rationale is that bronchial epithelial damage from infection accelerates epigenetic dysregulation; Bronchogen's chromatin-level effects may support restoration of normal epithelial gene expression after injury.
Pulmonary Immune Defense and Mucosal Immunity
Emerging Research
Local bronchial immune function — secretory IgA production, alveolar macrophage activity, bronchial mast cell regulation — declines with age. Bronchogen's tissue-specific action on bronchial epithelial cells may indirectly support the local immune niche by restoring the epithelial substrate that hosts these immune populations.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Bronchogen was developed at the St. Petersburg Institute of Bioregulation and Gerontology. Authentic pharmaceutical-grade Bronchogen is available as a lyophilized injectable from recognized Russian/Eastern European manufacturers. Products claiming "Bronchogen" without a clear tetrapeptide sequence (Ala-Glu-Asp-Ala) and lyophilized injection-grade preparation are suspect.
Verified Marker
Injectable-Grade Lyophilized Powder
As a research-grade injectable bioregulator, Bronchogen should be a white lyophilized powder reconstituted with bacteriostatic water or sterile saline. Clear, colorless solution post-reconstitution. No sediment or discoloration.
Quality Concern
Non-Pharmaceutical "Spray" or "Drop" Oral Claims
While oral supplement-grade Bronchogen capsules or sublingual drops exist (Cytogen product line), these have dramatically different bioavailability compared to the injectable form used in Khavinson research. Claims of bioequivalence between oral supplement and injectable Bronchogen are unsupported.
Quality Concern
Room-Temperature Shipping Without Cold Pack
Like all injectable peptide bioregulators, Bronchogen requires cold-chain shipping and refrigerated storage. Products shipped without temperature control raise integrity concerns about the peptide's folding and activity at time of use.
Khavinson development attribution.Existing stored entry reference; Existing stored entry reference Bronchogen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson's team targeting bronchopulmonary tissue — specifically the bronchi and bronchioles. It is one of the organ-specific cytomedins in the Khavinson system, designed to restore normal functional gene expression in aging or damaged bronchial epithelial cells.